标题
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-03-10
DOI
10.3389/fonc.2022.865350
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
- (2022) J. Matthijs Moll et al. PROSTATE
- ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
- (2021) Hao Tian et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
- (2021) Michael L. Mohler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.
- (2021) Ronan Le Moigne et al. JOURNAL OF CLINICAL ONCOLOGY
- Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
- (2021) Eva Estébanez-Perpiñá et al. Cancers
- A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
- (2021) Xuanrong Chen et al. Translational Andrology and Urology
- iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis
- (2021) Jibin Guan et al. ADVANCED FUNCTIONAL MATERIALS
- The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches
- (2021) Mark P Labrecque et al. ENDOCRINE-RELATED CANCER
- Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
- (2021) Linrong Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
- (2021) Sylvan C. Baca et al. Nature Communications
- Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
- (2021) Mamta Parikh et al. Scientific Reports
- PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
- (2021) Si-Min Qi et al. Frontiers in Pharmacology
- Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment
- (2021) Jian-Jia Liang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
- (2021) Claudia Enriquez et al. CANCER RESEARCH
- BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
- (2021) Dae-Hwan Kim et al. CLINICAL CANCER RESEARCH
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
- (2021) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular events in neuroendocrine prostate cancer development
- (2021) Yong Wang et al. Nature Reviews Urology
- Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
- (2021) Yuan Liu et al. Cell Death & Disease
- AR Splicing Variants and Resistance to AR Targeting Agents
- (2021) Mayuko Kanayama et al. Cancers
- Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
- (2021) Xiaonan Cong et al. Frontiers in Oncology
- The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance
- (2021) Che-Yuan Hu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
- (2021) Corinne Maurice-Dror et al. INVESTIGATIONAL NEW DRUGS
- The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
- (2021) Neha Singh et al. Nature Communications
- Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
- (2021) Paloma Cejas et al. Nature Communications
- Epigenetic modulations and lineage plasticity in advanced prostate cancer
- (2020) R. Ge et al. ANNALS OF ONCOLOGY
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain
- (2020) Shihong Peng et al. CELL BIOLOGY AND TOXICOLOGY
- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- Targeting RET Kinase in Neuroendocrine Prostate Cancer
- (2020) Halena R VanDeusen et al. MOLECULAR CANCER RESEARCH
- Determining the Drug-Like Properties of Ailanthone, a Novel Chinese Medicine Monomer with Anti-CRPC Activity
- (2020) Pan Hu et al. PLANTA MEDICA
- Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
- (2020) Hendrik Van Poppel et al. INTERNATIONAL JOURNAL OF UROLOGY
- Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
- (2020) Yukiyoshi Hirayama et al. Molecular Oncology
- Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways
- (2020) Milad Ashrafizadeh et al. Biomedicines
- The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells
- (2020) James E. Melnyk et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader
- (2020) Hang Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2
- (2020) Qiuli Liu et al. JOURNAL OF PATHOLOGY
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo
- (2020) Lijie Zhao et al. NEOPLASIA
- A review of the effects and molecular mechanisms of dimethylcurcumin (ASC‐J9) on androgen receptor‐related diseases
- (2020) Hang Hu et al. Chemical Biology & Drug Design
- Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
- (2020) Akshay D. Takwale et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC resistant to Second-Line Antiandrogen Therapy
- (2020) Geun Taek Lee et al. MOLECULAR CANCER THERAPEUTICS
- Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
- (2020) Shidong Lv et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
- (2019) Maria V. Luna Velez et al. ONCOGENE
- Rutaecarpine: A Promising Cardiovascular Protective Alkaloid from Evodia Rutaecarpa (Wu Zhu Yu)
- (2019) Kun-ming Tian et al. PHARMACOLOGICAL RESEARCH
- ONECUT2 is a driver of neuroendocrine prostate cancer
- (2019) Haiyang Guo et al. Nature Communications
- Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
- (2019) Fu-Ju Chou et al. EBioMedicine
- Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
- (2019) Davide Di Fusco et al. Frontiers in Pharmacology
- Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.
- (2019) Ronan Le Moigne et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression
- (2019) Yinan Li et al. EUROPEAN UROLOGY
- The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer
- (2019) Martina Pagliuca et al. DRUGS
- Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer
- (2019) Miguel Reina-Campos et al. CANCER CELL
- Preclinical toxicology and toxicokinetic evaluation of ailanthone, a natural product against castration-resistant prostate cancer, in mice
- (2019) Shuowen Tang et al. FITOTERAPIA
- ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
- (2019) Chi-Ping Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Nobiletin and Derivatives: Functional Compounds from Citrus Fruit Peel for Colon Cancer Chemoprevention
- (2019) Goh et al. Cancers
- Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
- (2019) Suriyan Ponnusamy et al. CLINICAL CANCER RESEARCH
- N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
- (2019) Adeline Berger et al. JOURNAL OF CLINICAL INVESTIGATION
- A novel small molecule targets androgen receptor and its splice variants in castration-resistant prostate cancer
- (2019) Zhenyu Yang et al. MOLECULAR CANCER THERAPEUTICS
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
- (2019) Qin Feng et al. Frontiers in Oncology
- The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
- (2019) Alastair Davies et al. ENDOCRINE-RELATED CANCER
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel androgen receptor antagonist JJ‐450 inhibits enzalutamide‐resistant mutant AR F876L nuclear import and function
- (2019) Zeyu Wu et al. PROSTATE
- Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
- (2018) Heini M. L. Kallio et al. BRITISH JOURNAL OF CANCER
- Androgen receptor (AR) degradation enhancer ASC-J9 ® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth
- (2018) Max A. Cheng et al. CANCER LETTERS
- ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3
- (2018) WanYing Lin et al. CANCER LETTERS
- Androgen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Antiandrogens
- (2018) E. David Crawford et al. JOURNAL OF UROLOGY
- A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
- (2018) Michael T. Schweizer et al. PLoS One
- Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies
- (2018) Loredana Puca et al. Cold Spring Harbor Perspectives in Medicine
- ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis
- (2018) Yuanjie Niu et al. CANCER LETTERS
- Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer
- (2018) Lanbo Xiao et al. CANCER RESEARCH
- Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
- (2018) Yan Zhang et al. Nature Communications
- A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network
- (2018) Ahn R. Lee et al. EBioMedicine
- Alternative RNA splicing of the GIT 1 gene is associated with neuroendocrine prostate cancer
- (2018) Ahn R. Lee et al. CANCER SCIENCE
- Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone
- (2017) Khalid Z Masoodi et al. ENDOCRINOLOGY
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer
- (2017) Bin Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
- (2017) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
- (2017) Chengfei Liu et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules
- (2017) Khalid Z. Masoodi et al. MOLECULAR CANCER THERAPEUTICS
- Androgen Signaling in Prostate Cancer
- (2017) Charles Dai et al. Cold Spring Harbor Perspectives in Medicine
- A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer
- (2017) Song Liu et al. eLife
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
- (2016) Eva De Mol et al. ACS Chemical Biology
- Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells
- (2016) Paul A. Johnston et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L
- (2016) Ronghao Wang et al. CANCER LETTERS
- ASC-J9®, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals
- (2016) Simeng Wen et al. CANCER LETTERS
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells
- (2016) Simeng Wen et al. MOLECULAR CARCINOGENESIS
- Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
- (2016) Yundong He et al. Nature Communications
- CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy
- (2016) Huiying Sun et al. Hormones & Cancer
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
- (2015) Shinichi Yamashita et al. NEOPLASIA
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells
- (2014) Javid A. Dar et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors
- (2013) Feng Sun et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods
- (2013) Huifang Li et al. Journal of Chemical Information and Modeling
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
- (2013) Ravi Shashi Nayana Munuganti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Genomics-Guided Discovery of Thailanstatins A, B, and C As Pre-mRNA Splicing Inhibitors and Antiproliferative Agents from Burkholderia thailandensis MSMB43
- (2013) Xiangyang Liu et al. JOURNAL OF NATURAL PRODUCTS
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
- (2012) Kuo-Pao Lai et al. AMERICAN JOURNAL OF PATHOLOGY
- Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice
- (2012) Jun Yang et al. Nanomedicine
- Alternatively spliced androgen receptor variants
- (2011) Scott M Dehm et al. ENDOCRINE-RELATED CANCER
- Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo
- (2011) Justin B. Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.
- (2011) Nathan A. Lack et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Adeno-associated virusâdelivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: A preclinical study
- (2009) Aijing Sun et al. INTERNATIONAL JOURNAL OF CANCER
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors
- (2008) R. Snoek et al. CLINICAL CANCER RESEARCH
- Characterization of Nuclear Import of the Domain-Specific Androgen Receptor in Association with the Importin α/β and Ran-Guanosine 5′-Triphosphate Systems
- (2008) Natsuko Kaku et al. ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search